-BPL has signed an agreement with a global company (Fortune500) to collaborate in the development of a new protein-based drug candidate.
According to the agreement, BPL will develop a bacterial fermentation, refolding process,
purification and formulation as well as the related analytical testing methods.
For this project, BPL will utilize its know-how and experience in recombinant protein expression in bacterial systems, purification and product formulation.
-BPL has signed an agreement with US based company for the development and production of series of enzymes and their immobilization to solid matrices. BPL will utilize its know-how and experience in recomninant enzyme expression in bacterial systems, purification and product formulation.
-BPL is relocating to a new facility in Yavne- 15 Nahal Snir st. The facility, designed and constructed specially according to BPL's plans and requirements, will be ready by ebd December 2017. BPL will start operation in the new facility by beginning January 2018.
We are a CDO/CMO for the biotech sector located in Israel.
Our team is highly experienced in process development and production using different expression systems:
-Mammalian (CHO, HEK)
-Bacterial (E.coli, Bacillus, Streptococcus..)
-Yeast (K.Lactis, Pichia..)
We are focused in development of biopharmacuticals, recombinant or native- either drug, vaccine, diagnostic etc.
However, we have vast experience with development of enzymes and protein based reagents intended for non-pharmacutical purposes.
We are Client Oriented, commited to tailor project scope and cost for each Customer to fit its needs and constrains.
You are cordially invited to get in for a cup of coffee or set a conference call or SKYPE to discuss your project and get a quote.
BPL Biologics 19 Hidekel st. Yavne POB 13240 8122614 Israel Tel: +972.76.548.8118 US: +973.723.9000